Supreme Court Rebuffs Pharma Challenge to Drug Price Law, Upholding Biden-Era Policy
JNJ sits 52% above its 52-week low of $149.04.
Summary
The U.S. Supreme Court has declined to hear appeals from several pharmaceutical companies, including Johnson & Johnson (via its Janssen unit) and Bristol Myers Squibb, effectively upholding the Biden administration's drug price negotiation plan. This decision solidifies the government's ability to negotiate prices for certain high-expenditure Medicare drugs under the Inflation Reduction Act. For pharmaceutical companies, this is a significant negative development as it removes a key legal avenue to challenge a policy expected to reduce drug revenues. Traders should monitor the ongoing implementation of the price negotiation program and its specific financial impact on affected drug portfolios.
At the time of this announcement, JNJ was trading at $226.23 on NYSE in the Life Sciences sector, with a market capitalization of approximately $544.6B. The 52-week trading range was $149.04 to $251.71. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.